Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | PHF2 | CTRPv2 | pan-cancer | AAC | 0.16 | 8e-07 |
mRNA | RCOR2 | CTRPv2 | pan-cancer | AAC | 0.18 | 8e-07 |
mRNA | FSD1L | CTRPv2 | pan-cancer | AAC | 0.16 | 8e-07 |
mRNA | SEC11A | CTRPv2 | pan-cancer | AAC | -0.16 | 8e-07 |
mRNA | MANBAL | CTRPv2 | pan-cancer | AAC | -0.21 | 8e-07 |
mRNA | RP13-512J5.1 | CTRPv2 | pan-cancer | AAC | -0.16 | 8e-07 |
mRNA | TOP2B | CTRPv2 | pan-cancer | AAC | 0.18 | 8e-07 |
mRNA | HMX2 | CTRPv2 | pan-cancer | AAC | 0.16 | 9e-07 |
mRNA | MDM4 | CTRPv2 | pan-cancer | AAC | 0.19 | 9e-07 |
mRNA | ZNF608 | CTRPv2 | pan-cancer | AAC | 0.16 | 9e-07 |